{"disease":{"id":"absence","name":"absence"},"drugs":{"marketed":[{"drug_id":"valproate","indication_name":"Simple and Complex Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Valproate","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its anti-epileptic effects."},{"drug_id":"valproate","indication_name":"Multiple Seizure Types Including Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Valproate","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its anti-epileptic effects."},{"drug_id":"clonazepam","indication_name":"Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klonopin","generic_name":"clonazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"valproate-sodium","indication_name":"Simple and Complex Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALPROATE SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its antiepileptic effects."},{"drug_id":"valproate-sodium","indication_name":"Multiple Seizure Types Including Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALPROATE SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its antiepileptic effects."},{"drug_id":"sodium valproate","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"zarontin","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zarontin","generic_name":"Ethosuximide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-dependent T-type calcium channel subunit alpha-1G","drug_class":"Succinimide","quality_score":10,"revenue":null,"mechanism":"Suppresses paroxysmal three cycle per second spike and wave activity associated with absence seizures."},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"riv","indication_name":"HIV-1 infection in combination with other antiretroviral agents in pediatric patients 4 weeks of age and older and weighing at least 3 kg in the absence of antiretroviral treatment failure and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater and with no prior antiretroviral therapy and with viral load 100,000 copies/mL or less and with CD4 percentage 25% or greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Riv","generic_name":"riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"HIV-1 protease","drug_class":"Protease Inhibitors","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"lorazepam","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ativan","generic_name":"lorazepam","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clonazepam","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klonopin","generic_name":"clonazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ethadione","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Didione","generic_name":"ethadione","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"ethadione","quality_score":null,"revenue":null,"mechanism":"Didione works by modulating the activity of neurons in the brain to control seizures."},{"drug_id":"prenderol","indication_name":"Childhood absence epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"2,2-Diethyl-1,3-Propanediol","generic_name":"prenderol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"prenderol","quality_score":null,"revenue":null,"mechanism":"Prenderol works by modulating the activity of certain neurotransmitters in the brain to reduce seizure frequency."},{"drug_id":"valproic-acid","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"acetazolamide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"phensuximide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Succitimal","generic_name":"PHENSUXIMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-gated T-type calcium channel","drug_class":"phensuximide","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"testosterone-undecanoate","indication_name":"Deficiency or absence of endogenous testosterone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aveed","generic_name":"TESTOSTERONE UNDECANOATE","company_name":"Marius","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen","quality_score":70,"revenue":null,"mechanism":"Aveed works by binding to androgen receptors in the body, mimicking the effects of natural testosterone."},{"drug_id":"paramethadione","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paradione","generic_name":"PARAMETHADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-gated T-type calcium channel","drug_class":"paramethadione","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ethosuximide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zarontin","generic_name":"ETHOSUXIMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-dependent T-type calcium channel subunit alpha-1G","drug_class":"Anti-epileptic Agent [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"methsuximide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celontin","generic_name":"METHSUXIMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-gated T-type calcium channel","drug_class":"Anti-epileptic Agent","quality_score":0,"revenue":null,"mechanism":"Celontin works by blocking the activity of voltage-gated T-type calcium channels in the brain."},{"drug_id":"mesuximide","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"mesuximide","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_2","molecular_target":"Voltage-gated T-type calcium channel","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"divalproex","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"klonopin","indication_name":"Absence seizure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Klonopin","company_name":"Par Pharmaceutical, Inc.","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":31,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03678077","title":"Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury","phase":"","overall_status":"COMPLETED","enrollment_count":45777,"lead_sponsor_name":"University of Copenhagen","has_results":false},{"nct_id":"NCT03382080","title":"A School-based Intervention Project to Increase Completion of Upper Secondary School in Norway","phase":"NA","overall_status":"COMPLETED","enrollment_count":3500,"lead_sponsor_name":"University of Bergen","has_results":false},{"nct_id":"NCT05006976","title":"A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1180,"lead_sponsor_name":"Nordlandssykehuset HF","has_results":false},{"nct_id":"NCT03002987","title":"Active Pregnancy Policy at Work. Greater Wellbeing and Lower Sickness Absence","phase":"NA","overall_status":"COMPLETED","enrollment_count":866,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT06331260","title":"Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06187428","title":"The PainSMART Research Program: Evaluating a Pain Education Strategy for Patients Seeking Primary Care Physiotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":494,"lead_sponsor_name":"Kajsa Johansson","has_results":false},{"nct_id":"NCT05154019","title":"Managing Minds at Work: A Feasibility Pilot Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT04666610","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT04439656","title":"Detecting Absence Seizures Using Eye Tracking","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Rachel Kuperman","has_results":false},{"nct_id":"NCT06061835","title":"Non-contrast Magnetic Resonance Angiography in Deep Inferior Epigastric Perforator Flap Breast Reconstruction Planning","phase":"NA","overall_status":"UNKNOWN","enrollment_count":135,"lead_sponsor_name":"I.M. Sechenov First Moscow State Medical University","has_results":false},{"nct_id":"NCT04543097","title":"Work And Vocational advicE Study - Effectiveness of Adding a Brief Vocational Support Intervention to Usual Primary Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Keele University","has_results":false},{"nct_id":"NCT06315322","title":"A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT04615442","title":"ECV - Epihunter Clinical Validation","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Epihunter NV","has_results":false},{"nct_id":"NCT04619849","title":"Electrophysiological Changes Based on the Palmaris Longus","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Istanbul Medipol University Hospital","has_results":false},{"nct_id":"NCT05258019","title":"Site Preservation After Tooth Extraction","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":88,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05109234","title":"A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT06004778","title":"The Effect of Motivational Support Program Applied to Adolescents on Sleep Quality and Academic Achievement","phase":"NA","overall_status":"UNKNOWN","enrollment_count":84,"lead_sponsor_name":"Istanbul University - Cerrahpasa","has_results":false},{"nct_id":"NCT06991660","title":"The Effect of Sleep Hygiene Education Given in Line With the Health Promotion Model on Sleep Quality and Menopause Symptoms","phase":"NA","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Inonu University","has_results":false},{"nct_id":"NCT06093490","title":"Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Eysz, Inc.","has_results":false},{"nct_id":"NCT05106855","title":"Comparative Study of Immediate Single Unit Implants in Early Loading Protocols, With or Without Photobiomodulation.","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"University of Santiago de Compostela","has_results":false},{"nct_id":"NCT06310772","title":"Assessing Comorbidities in Epilepsy Using Eye Movement Recordings","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Eysz, Inc.","has_results":false},{"nct_id":"NCT00144872","title":"LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04799795","title":"Objective EEG Bed Side Assessment of Impaired Conscious Awareness in Epilepsy","phase":"","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"University Hospital Schleswig-Holstein","has_results":false},{"nct_id":"NCT04274179","title":"Ketogenic Diet for New-Onset Absence Epilepsy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT07041502","title":"Aut-CARE Intervention to Improve Cognitive and Emotional Functioning in Young Adults on the Autism Spectrum","phase":"","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT07244185","title":"Comparison of Osseodensification and Conventional Drilling on the Stability of Tapered and Cylindrical Implants.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Worood Adnan Akram","has_results":false},{"nct_id":"NCT06194838","title":"Clinical Outcomes With Non-Powered vs. Powered Prosthetic Knees by K2-level Amputees","phase":"NA","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Liberating Technologies, Inc.","has_results":false},{"nct_id":"NCT03817151","title":"Clinical Observation of the Transscleral Suture Fixation of Posterior Chamber Intraocular Lens in Eyes With Inadequate Capsule Support","phase":"","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06401538","title":"BMB-101 in Absence Epilepsy and DEE","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Bright Minds Biosciences Pty Ltd","has_results":false},{"nct_id":"NCT03336242","title":"Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Radius Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06218238","title":"A Biomechanical Evaluation of the Ossur Power Knee in Persons With Transfemoral Amputation","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT07103798","title":"Effect of a Microprocessor-controlled Prosthetic Knee Joint on K2 Level Ambulators","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06045702","title":"Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT03277430","title":"Uterus Transplantation From Live Donors and From Deceased Donors - Clinical Study","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Institute for Clinical and Experimental Medicine","has_results":false},{"nct_id":"NCT05647499","title":"Evaluating the Back 2 School Program in a Norwegian Setting: A Multicenter Pilot Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"University of Tromso","has_results":false},{"nct_id":"NCT04899050","title":"Epidiolex in Typical Absence Seizures","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"University of South Florida","has_results":false},{"nct_id":"NCT05267639","title":"Clinical Outcomes With Passive MPKs vs. Powered Prosthetic Knees","phase":"NA","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Liberating Technologies, Inc.","has_results":true},{"nct_id":"NCT04484805","title":"Socket Cooling Effectiveness Take Home Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Liberating Technologies, Inc.","has_results":true},{"nct_id":"NCT07521371","title":"Intranasal Insulin for Autism Spectrum Disorder in Children and Young Adults Aged 4 to 21 Years","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":12,"lead_sponsor_name":"Healing Hope International","has_results":false},{"nct_id":"NCT03355300","title":"Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Radius Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05966636","title":"LASER Pilot Project","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06769659","title":"A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"NeuroPro Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06153186","title":"Flunarizine for Treatment Resistant Absence Epilepsy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT00008450","title":"Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT05038566","title":"Dexterous Partial Hand Prosthesis Outcomes","phase":"NA","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Liberating Technologies, Inc.","has_results":true},{"nct_id":"NCT03676543","title":"Mutual Interactions Between Absence Epilepsy Seizures and the Integration of Sensory Stimuli","phase":"NA","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT02928510","title":"Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma","phase":"","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03690245","title":"Initiation of Resuscitation While Attached to the Cord With Congenital Heart Disease","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT05840601","title":"Evaluation of Dexterous Terminal Device","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Liberating Technologies, Inc.","has_results":false}],"total":49},"guidelines":[],"source":"Drug Landscape verified database"}